Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Photosensitizer

Adv Sci (Weinh). 2022 Oct;9(29):e2202914. doi: 10.1002/advs.202202914. Epub 2022 Aug 18.

Abstract

Immunotherapy, the most promising strategy of cancer treatment, has achieved promising outcomes, but its clinical efficacy in pancreatic cancer is limited mainly due to the complicated tumor immunosuppressive microenvironment. As a highly inflammatory form of immunogenic cell death (ICD), pyroptosis provides a great opportunity to alleviate immunosuppression and promote systemic immune responses in solid tumors. Herein, membrane-targeted photosensitizer TBD-3C with aggregation-induced emission (AIE) feature to trigger pyroptosis-aroused cancer immunotherapy via photodynamic therapy (PDT) is applied. The results reveal that pyroptotic cells induced by TBD-3C could stimulate M1-polarization of macrophages, cause maturation of dendritic cells (DCs), and activation of CD8+ cytotoxic T-lymphocytes (CTLs). Pyroptosis-aroused immunological responses could convert immunosuppressive "cold" tumor microenvironment (TME) to immunogenic "hot" TME, which not only inhibits primary pancreatic cancer growth but also attacks the distant tumor. This work establishes a platform with high biocompatibility for light-controlled antitumor immunity and solid tumor immunotherapy aroused by cell pyroptosis.

Keywords: aggregation-induced emission; immunotherapy; pancreatic cancer; photodynamic therapy; pyroptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunologic Factors / pharmacology
  • Immunotherapy / methods
  • Pancreatic Neoplasms* / therapy
  • Photosensitizing Agents / pharmacology
  • Pyroptosis
  • Tumor Microenvironment*

Substances

  • Immunologic Factors
  • Photosensitizing Agents